ClinicalTrials.gg
RecruitingNCT07280338IEDOFUpdated Jun 16, 2026

Emotional Intelligence and Chronic Orofacial Pain

An observational study in Chronic Pain, sponsored by University Hospital, Brest. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by University Hospital, Brest · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
88
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 135 studies in Chronic Pain with a site in France — 35 open to participants now, 39 under way, 2 of them phase 3. Chronic Pain · France.

Planned enrollment
48th of 68
88 · median 160
Started
2026
with 10 others
Observational
68 of 135
15 open now
Primary completion
2027-02
later than 12 of 38 live
Registered
120th of 135
by date
Lead sponsor
4 of 135
University Hospital, Brest

Among the 135 studies in Chronic Pain with a site in France, this one is the 48th largest by planned enrollment of the 68 observational ones that give a count, is one of 11 that started in 2026, is one of 68 observational ones, reaches primary completion later than 12 of the 38 other live ones, and was the 120th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

35 of the 135 studies in Chronic Pain with a site in France are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 135 studies in Chronic Pain with a site in France, or all of them as a file.
02

Study summary

Chronic pain, lasting more than three months, is a widespread health issue that negatively impacts daily life, leading to significant emotional distress and functional impairment. Emotional intelligence, defined as the ability to recognize and manage one's own emotions as well as those of others, has been linked to better communication skills and reduced stress, which is a well-known risk factor for chronic pain. Studies have highlighted a correlation between emotional intelligence and certain chronic pain conditions, such as fibromyalgia and migraines. However, no research has yet explored its role in painful temporomandibular disorders (TMD). Given the strong involvement of psychosocial factors in TMD etiology, a better understanding of these elements could improve pain management and pave the way for preventive interventions.

Read the detailed description

This project aims to compare emotional intelligence and various psychosocial factors (anxiety, depression, coping, emotional regulation) between patients with painful temporomandibular disorder (TMD) and a control group without TMD or chronic pain. The study is based on the administration of validated French-language questionnaires during routine dental medicine consultations. Each participant completes these questionnaires in approximately 15 minutes, without any modification to their care. The data collected will help assess the relationships between orofacial pain and emotional factors to improve the understanding and management of affected patients.

03

Conditions studied

  • Chronic Pain

Browse trials for

Keywords

  • Emotional intelligence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Regarding the evaluated population (cases), approximately 30 patients are seen each week in the oral health service for chronic orofacial pain consultations. About 60% of these patients have a diagnosis of painful TMD, which is around 18 patients per week. Including 44 patients in this study over a 6-month period thus seems feasible.

Regarding the control population, more than 50 patients are seen daily in oral rehabilitation consultations at the oral health service of the CHU de Brest. These controls will be matched in gender and age (+/- 5 years) with the studied population (cases). The significant proportion of these patients should allow for the feasibility of this matching.

Eligibility criteria

Inclusion Criteria:

For all subjects:

Major subject

  • Non-opposition obtained
  • For subjects in the TMD group:

Diagnosis of temporomandibular dysfunction -No other diagnosis of chronic pain

For subjects in the control group:

-No diagnosis of chronic pain

Non inclusion Criteria:

  • Subject not understanding French
  • Subject under legal protection (guardianship or curatorship)
  • Refusal to participate
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
88 participants (estimated)
Patient registry
No

Groups and cohorts

  • Evaluation of the potential link between emotional intelligence and chronic orofacial pain.

    All included subjects will have the same participation, which consists of completing several standardized questionnaires. These questionnaires assess various psychological and emotional aspects, including anxiety and depressive disorders (HADS questionnaire), coping strategies (Brief-COPE score), emotional regulation (ERS score), fatigue level (EVA scale), and emotional intelligence (TEIQue-SF questionnaire) to compare scores between the DTM group and the control group. Additionally, sociodemographic and psychosocial criteria will be collected to refine the analysis of the results. The completion of these questionnaires is part of routine consultations and does not alter the patients' standard care.

    Other: Questionnaire and Physical Exam

Interventions

  • OtherQuestionnaire and Physical Exam

    All included subjects will be required to complete the following questionnaires: Hospital Anxiety and Depression Scale (HADS) Brief-COPE for coping assessment Emotion Reactivity Scale (ERS) for emotional regulation Visual Analog Scale (VAS) for fatigue assessment Sociodemographic and psychosocial evaluation Trait Emotional Intelligence Questionnaire - Short Form (TEIQue-SF) for emotional intelligence assessment

06

What researchers measure

Primary outcomes

  1. Measurement of emotional intelligence score between both groups

    Measurement of emotional intelligence score assessed by the TEIQue-SF questionnaire : The short version consists of 33 items assessing four factors: well-being, self-control, emotionality, and sociability. Each item is rated on a Likert scale ranging from 1 ("strongly disagree") to 7 ("strongly agree").

    Time frame: Day 0

Secondary outcomes

  1. Measurement of anxiety disorders between both groups

    Measurement of anxiety disorders between the two groups via the HAD-S questionnaire The HAD scale is a validated instrument in French, used to screen for anxiety and depressive disorders. It consists of 14 items scored from 0 to 3. Seven questions relate to anxiety (total A) and the other seven to the depressive dimension (total D), thus providing two scores (maximum score for each = 21). This questionnaire is routinely used during consultations in the oral health service and systematically used during specialized consultations for orofacial pain.

    Time frame: Day 0

  2. Measurement of the coping score between both groups

    Measurement of the coping score assessed by the Brief-COPE questionnaire This instrument is an abbreviated version of the COPE inventory with 28 items. It includes 14 scales that assess distinct dimensions of coping: active coping, planning, instrumental social support seeking, emotional social support seeking, emotional expression, behavioral disengagement, distraction, blaming, positive reinterpretation, humor, denial, acceptance, religion, and substance use.

    Time frame: Day 0

  3. Measurement of emotional regulation score between both groups

    Measurement of emotional regulation score assessed by the ERS questionnaire The ERS is a self-report questionnaire with 21 items designed to measure, using a single tool, three dimensions of emotional reactivity: emotional sensitivity, intensity, and persistence of emotions. Each item is rated on a Likert scale ranging from 0 ("does not apply to me at all") to 4 ("applies to me perfectly").

    Time frame: Day 0

  4. Measurement of fatigue score between both groups

    Measurement of fatigue score assessed by an EVA scale (From 0 to 10)

    Time frame: Day 0

  5. Measurement of Depression disorders between both groups

    Measurement of depression disorders between both groups via the HAD-S questionnaire The HAD scale is a validated instrument in French, used to screen for anxiety and depressive disorders. It consists of 14 items scored from 0 to 3. Seven questions relate to anxiety (total A) and the other seven to the depressive dimension (total D), thus providing two scores (maximum score for each = 21). This questionnaire is routinely used during consultations in the oral health service and systematically used during specialized consultations for orofacial pain.

    Time frame: Day 0

07

Study locations

1 of 1 sites recruiting
  • CHU DE BREST - Médecine bucco-dentaire
    Brest, 29200, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

Of 337 non-industry observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 56. This study's planned 12 months is below that.

Counting every sponsor, half of 363 studies reached it within 24 months; a quarter within 12 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Dec 12, 2025
StartActual
Feb 9, 2026
Primary completionEst.
Feb 9, 2027
CompletionEst.
Feb 9, 2027
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07280338
Responsible party
Sponsor
First posted
Dec 12, 2025
Start date
Feb 9, 2026
Primary completion
Feb 9, 2027 (estimated)
Completion
Feb 9, 2027 (estimated)
Last update
Jun 16, 2026

Study contacts

Anais LE FUR-BONNABESSE, Dr
Contact
Anais.lefur-bonnabesse@chu-brest.fr
0298223330

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion